ArticleScientific reports2025
Pharmacokinetic, toxicological, and molecular interaction assessment of ginger-derived phenolics for SARS-CoV-2 main protease Inhibition.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Effects of lawsone and lawsone methyl ether on cyclooxygenase activity, redox balance, and organ-specific toxicity: An integrated computational and experimental study.Toxicology reports · 2026Article
- Disrupting virulence: in silico discovery of MexL inhibitors to block pyocyanin biosynthesis in Pseudomonas aeruginosa.Archives of microbiology · 2026Article
- Functional and Structural Insights into Lipases Associated with Fruit Lipid Accumulation inBiomolecules · 2026Article
- Mechanistic Evaluation of Radical Scavenging Pathways in Ginger Phenolics: A DFT Study of 6-Gingerol, 6-Shogaol, and 6-Paradol.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants are considered rich sources of bioactive compounds with potential antiviral properties. In this study, the inhibitory effects of major phenolic compounds from Zingiber officinale (ginger), including gingerol, paradol, and shogaol, were investigated against the main protease (Mpro) of SARS-CoV-2, a critical enzyme for viral replication. The three-dimensional structures of the ligands and target protein were retrieved from PubChem and the RCSB Protein Data Bank, respectively. The pharmacokinetic and toxicity profiles of the compounds were assessed using the SwissADME and ProTox-II servers, which revealed favorable ADMET characteristics and a low toxicity profile for all selected compounds. Molecular docking was conducted using AutoDock 4.2 to predict the binding affinity and interaction modes of the ligands with Mpro. Among the tested compounds, shogaol exhibited the strongest binding affinity (- 9.95 kcal/mol) and formed stable hydrogen and hydrophobic interactions with key active site residues. To validate the docking results and further explore the stability of the ligand-protein complexes under physiological conditions, molecular dynamics (MD) simulations were performed for 500 ns using the GROMACS software. The MD analysis showed that the shogaol-Mpro complex had the lowest RMSD and consistent hydrogen bonding throughout the simulation, confirming its stable binding behavior. These findings suggest that ginger-derived phenolic compounds, particularly shogaol, may serve as promising candidates for the development of novel therapeutics targeting COVID-19 main protease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.